

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 07-1-2008

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 22-9-2007 TO BE PUBLISHED ON 08-1-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1104/2007	<u>17-9-2007</u> John Franco Franchi United Kingdom (Priority 18-9-2006 US)	“Secure universal transaction system”
1105/2007	Arena Pharmaceuticals, Inc. USA (Priority 17-10-06 US)	“Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto”
1106/2007	Arena Pharmaceuticals, Inc. USA (Priority 03-10-06 US)	“Pyrazole derivatives as modulators of the 5-HT _{2A} serotonin receptor useful for the treatment of disorders related thereto”
1107/2007	<u>18-9-2007</u> Ortloff Engineers, Ltd. USA (Priority 28-9-06 USA)	“Hydrocarbon gas processing”
1108/2007	<u>19-9-2007</u> Wyeth, USA (Priority 19-9-06 USA)	“Use of LXR modulators for the prevention and treatment of skin aging”
1109/2007	Wyeth, USA (Priority 19-9-06 USA)	“Use of LXR agonists for the treatment of osteoarthritis”
1110/2007	Eisai R&D Management Co. Ltd., Japan (Priority 26-5-04 Japan) Divisional	“A salt of a cinnamide compound for reducing amyloid beta (AB) production”
1111/2007	<u>20-9-2007</u> Glaxo Group Limited, United Kingdom (Priority 22-9-06 GB)	Novel compounds”
1112/2007	Novartis AG,	“Method of manufacturing tablets

	Switzerland (Priority 22-9-06 US)	containing pharmacologically active agents”
1113/2007	<u>21-9-2007</u> AstraZeneca AB Sweden (Priority 29-9-06 USA)	“Novel compounds 480”
1114/2007	<u>22-9-2007</u> NSNGMBH & Co, KG. Germany (Priority 26-9-06 Italy)	“Method and system for deploying an application”
1115/2007	Boehringer Ingelheim International GmbH, Germany (Priority 25-9-06 USA)	“Compounds which modulate the CB2 receptor”
1116/2007	Merck and Co, Inc. USA (Priority 03-10-06 US)	“Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use”
1117/2007	Danisco US, Inc. USA (Priority 22-9-06 USA)	“Novel pectate lyase and method of use for bio-scouring”

